Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Average Rating of “Hold” by Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given an average recommendation of “Hold” by the five research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $17.6667.

AUPH has been the topic of several analyst reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $10.00 to $21.00 in a report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th.

Aurinia Pharmaceuticals Trading Up 7.0%

NASDAQ:AUPH opened at $14.93 on Friday. The firm has a fifty day simple moving average of $12.22 and a two-hundred day simple moving average of $10.12. Aurinia Pharmaceuticals has a 12 month low of $6.55 and a 12 month high of $16.20. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 34.63 and a beta of 1.30. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. The company had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Aurinia Pharmaceuticals will post 0.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AUPH. Nuveen LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $10,014,000. Qube Research & Technologies Ltd increased its holdings in Aurinia Pharmaceuticals by 45.1% during the second quarter. Qube Research & Technologies Ltd now owns 1,242,512 shares of the biotechnology company’s stock worth $10,524,000 after buying an additional 386,364 shares during the last quarter. Jupiter Asset Management Ltd. raised its position in Aurinia Pharmaceuticals by 24.1% in the second quarter. Jupiter Asset Management Ltd. now owns 933,862 shares of the biotechnology company’s stock worth $7,910,000 after acquiring an additional 181,093 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Aurinia Pharmaceuticals by 34.1% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 746,229 shares of the biotechnology company’s stock valued at $6,000,000 after acquiring an additional 189,775 shares during the last quarter. Finally, Trexquant Investment LP boosted its stake in Aurinia Pharmaceuticals by 58.5% in the first quarter. Trexquant Investment LP now owns 700,638 shares of the biotechnology company’s stock valued at $5,633,000 after acquiring an additional 258,620 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.